3.1.3.43	(1S)-1,5-anhydro-1-{[(1R,2R,3R,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-methoxycyclohexyl]methyl}-D-galactitol	i.e. C-INS-2-OH the deaminated analogue of C-INS-2	714447	
3.1.3.43	(1S)-2-amino-1,5-anhydro-2-deoxy-1-{[(1R,2R,3R,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-methoxycyclohexyl]methyl}-D-galactitol	i.e. C-INS-2, the C-glycoside of INS-2	714447	
3.1.3.43	2-tetradecylglycidate	together with insulin	94896	
3.1.3.43	4-O-beta-D-galactosaminyl-3-O-methyl-D-chiro-inositol	i.e. INS-2, allosteric activation, docking study using crystal structure of the enzyme PDHP1, PDB ID 2PNQ, and mechanism, overview	714447	
3.1.3.43	Ca2+	for isozyme PDP1c, simultaneous presence of Ca2+ and E2 component of substrate is required	650417	
3.1.3.43	Ca2+	stimulates PDP1 at micromolar concentrations	642164	
3.1.3.43	cysteine	reverses glyoxylate inhibition	94885	
3.1.3.43	Dichloroacetate	together with insulin	94896	
3.1.3.43	EGTA	-	94882	
3.1.3.43	inner lipoyl domain of dihydrolipoyl acetyltransferase	component of substrate complex, structural requirements for binding and activation	652240